Skip to content
Andarix
  • Home
  • About
  • Products
    • Tozaride ®
    • Companion Diagnostics
    • Our Science
  • News & Events
  • Contact
Andarix
  • Home
  • About
  • Products
    • Tozaride ®
    • Companion Diagnostics
    • Our Science
  • News & Events
  • Contact

Archive for February 2014

Andarix Receives Orphan Drug Designation from the FDA for Small Cell Lung Cancer

February 16, 2014

Novel Targeted and Personalized Medicine Approach to Lung Cancer ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancers announced today that Tozaride, the Company’s targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small…

Read More

Recent Posts

  • Andarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office
  • Andarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference
  • Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting.
  • Andarix Pharmaceuticals to present at the CBI Basket and Umbrella Trials for Oncology Conference
  • Andarix Pharmaceuticals Selected to Present at the 6th JCA-AACR Special Joint Conference on Lung Cancer

Recent Comments

    Archives

    • April 2019
    • October 2018
    • July 2018
    • February 2018
    • October 2017
    • September 2017
    • October 2015
    • September 2015
    • April 2015
    • December 2014
    • September 2014
    • July 2014
    • February 2014

    Categories

    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Home
    • About Us
    • Products
    • News & Events
    • Contact Us